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Abstract
Background: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) is currently used as a surrogate marker for
disease severity in pulmonary hypertension (PH). However, NT-proBNP tends to have a high variability and may
insufficiently correlate with hemodynamics and exercise capacity.
Methods: To investigate the association of NT-proBNP with hemodynamics and cardio-pulmonary exercise testing
(CPET) in 84 therapy-naive patients with precapillary PH.
Results: NT-proBNP levels were significantly correlated with hemodynamics and CPET parameters except for cardiac index,
diffusion capacity, PaO2 at peak exercise, and peak minute ventilation. NT-proBNP correlated best with hemodynamics and
CPET in women and patients >65 years. NT-proBNP correlated better with CPET in pulmonary arterial hypertension
compared to chronic thromboembolic PH (CTEPH).
Conclusion: NT-proBNP is associated with disease severity in precapillary PH. The association might be age- and gender-
dependent. NT-proBNP may insufficiently correlate with disease severity in CTEPH, possibly due to comorbidity.
Keywords: N-terminal pro-brain-type natriuretic peptide (NT-proBNP), Pulmonary arterial hypertension (PAH), Chronic
thromboembolic pulmonary hypertension (CTEPH), Exercise capacity, Hemodynamics, Age, Gender
Background
Pulmonary hypertension (PH) is defined as an increase
in mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg
at rest. In the presence of a pulmonary capillary wedge
pressure (PCWP) ≤ 15 mmHg, PH is hemodynamically
classified to be precapillary. Precapillary PH results from
different clinical conditions, such as pulmonary arterial
hypertension (PAH), PH due to lung diseases, chronic
thromboembolic PH (CTEPH), and PH with unclear
and/or multifactorial mechanisms [1].
Pressure overload of the right heart due to PH activates
the natriuretic peptide system. Brain-type natriuretic
peptide (BNP) is released in response to myocardial
stretch from cardiomyocytes, where it has been synthe-
sized as an inactive precursor (proBNP) and split into the
active hormone BNP and the inactive N-terminal frag-
ment (NT-proBNP) [2]. While BNP has a short half-life,
NT-proBNP is not further metabolized and is eliminated
only by renal excretion, resulting in a longer half-life.
Therefore, NT-proBNP is preferably used in clinical
routine as an indicator of myocardial dysfunction.
In PAH, serum NT-proBNP levels correlate with right
heart dysfunction and provide prognostic information at
the time of diagnosis and during follow-up assessments
[3, 4]. However, NT-proBNP tends to have a high
variability and should only be interpreted in the clinical
context, as NT-proBNP may insufficiently correlate with
hemodynamics and exercise capacity [1].
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We therefore investigated the association of serum
NT-proBNP with hemodynamics and functional capacity
in therapy-naïve patients with precapillary PH.
Methods
Study design and patient population
Between August 2009 and March 2016, 84 patients with
precapillary PH could be enrolled in the study. PH was
therapy-naive in all study participants. Patients with
serum creatinine levels >1.3 mg/dL and/or estimated
glomerular filtration rates <50 mL/min/1.73 m2 or signs
of acute right heart decompensation were excluded from
the trial. Relevant left heart disease was ruled out by
echocardiography in every patient included in the study.
All laboratory tests, cardiopulmonary exercise testing
(CPET), six minute walking testing (6MWT), and right
heart catheterization (RHC) were performed standar-
dised within three consecutive workdays. The study was
conducted with the approval of the local Ethics Commit-
tee. Data analysis was performed retrospectively.
Lung function tests
Pulmonary function tests included spirometry, body
plethysmography, and measurement of diffusing capacity
using the single-breath method (Master Screen Body
and MS-PFT, Jaeger, Cardinal Health, USA). The follow-
ing parameters were determined: forced vital capacity,
total lung capacity, forced expiratory volume in one
second, and diffusing capacity for carbon monoxide
(DLCO). Blood gas analysis (ABL 725, Radiometer,
Copenhagen, Denmark) was performed in arterialized
capillary blood from the ear lobe without supplemental
oxygen (O2).
CPET
CPET was performed using a standardized protocol
[5]. The work rate was continuously increased by 5–
15 watts/min to a maximum tolerated level on an
electromagnetically braked cycle ergometer (ViaSprint
150 p, Ergoline, Germany). Patients were encouraged
to exercise until symptoms were intolerable. Blood
gas analysis was done at rest and during peak exer-
cise. The heart rate was monitored continuously and
non-invasive blood pressure was taken every 2 min.
The maximum work rate was recorded. O2 uptake
(VO2), minute ventilation (Ve) and CO2 output
(VCO2) were measured breath by breath using an
adult facemask (Vmax spectra 229 D, Sensor Medics,
USA). O2 pulse, alveolar-arterial O2 difference
(AaDO2), and functional dead space ventilation (Vd/
Vt) were calculated as described before [5]. The an-
aerobic threshold (AT) was chosen at the peak VO2
at which the ventilatory equivalent for O2 (Ve/VO2)
increased, while the ventilatory equivalent for CO2
(Ve/VCO2) decreased or remained constant. Peak
VO2 was defined as the value of averaged data during
the final 15 s of exercise. The Ve/VCO2 slope was de-
termined as the linear regression slope of Ve and
VCO2 from the start of exercise until the respiratory
compensation point (the point in time at which venti-
lation is stimulated by acidaemia and the end-tidal
CO2 begins to decrease).
RHC
RHC was performed in all patients in order to confirm
precapillary PH. A thermodilution catheter (7.5 F
quadruple-lumen, balloon-tipped, flow-directed, “S” Tip
Swan-Ganz Catheter, Edwards Lifesciences, Irvine, USA)
was inserted via the right or left femoral vein.
Hemodynamic measurements were performed in supine
position and included heart rate, PCWP, PAP, and right
atrium pressure (RAP). O2 saturation was measured in
mixed venous blood samples (ABL 725, Radiometer,
Copenhagen, Denmark). The cardiac output was mea-
sured by thermodilution with 10 ml of sterile, ice-cold
isotonic (0.9%) saline, which was injected through the
right atrial lumen of the catheter; the drop in
temperature at the distal thermistor was then recorded.
The injectate temperature was determined by a thermis-
tor, which was placed directly behind the right atrial in-
let of the catheter. Cardiac output was calculated using a
computer system (Com-2, Cardiac Output Computer,
Edwards Lifesciences, Irvine, USA). In each patient, a
minimum of three measurements was performed; the
mean value was calculated if the variability of values was
less than 10%. The pulmonary vascular resistance (PVR)
was calculated using a standard formula [PVR = (mean
PAP – PCWP) / cardiac output].
NT-proBNP
Serum NT-proBNP levels were measured using a one-step
sandwich chemiluminescent immunoassay (Dimension
Vista™ System, Siemens Healthcare Diagnostics Inc.,
Newark, USA). Blood samples were taken at rest shortly
before performing CPET. Values >125 pg/ml were consid-
ered elevated for patients younger than 75 years and
>450 pg/ml for those older than 75 years [6]. In order to
avoid an underestimation or overestimation of absolute
values, measured NT-proBNP levels were divided by the
age-adjusted normal upper range to calculate the normal-
ized NT-proBNP ratio. Consequently, elevated levels
result in a normalized NT-proBNP ratio > 1.
Statistics
Statistical analysis was performed using IBM SPSS Sta-
tistics Version 23.0. Continuous variables characterized
by a normal distribution are shown as means ± standard
error of mean (SEM). Variables without such a
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distribution are expressed as medians with range. The
Shapiro-Wilk test was used to check the normality of
distribution. Nominal parameters were expressed as
counts with percentage of total. Correlation analysis was
performed using the Spearman correlation index. All re-
sults were tested for two-sided significance. P-values
<0.05 were considered statistically significant.
Results
Patients’ characteristics
The characteristics of the study population are summa-
rized in Table 1. 84 patients could be included in the
trial (46 women, 38 men, mean age 70.6 years). In all
subjects, precapillary pulmonary hypertension was diag-
nosed with a mean PAP of 41.0 mmHg and a median
PVR of 7.4 Wood units. PAH was diagnosed in 75 pa-
tients, 12 study participants suffered from CTEPH. The
median NT-proBNP level was 1500 pg/ml with a median
NT-proBNP ratio of 7.53.
The mean 6MWT distance was 305 m; the median
work capacity 47 watts. The mean DLCO was measured
to be 52.9% of predicted, the mean AaDO2 was
49.0 mmHg. Mean VO2 was determined to be 13.0 ml/
min/kg with a median O2 pulse at peak exercise of
8.3 ml/min/beat. Mean Vd/Vt was 37.1%. The mean Ve/
VO2 ratio was calculated to be 40.5 with a mean Ve/
VCO2 slope of 44.2. The mean haemoglobin concentra-
tion was 14.3 ± 1.2 mg/dl with no significant differences
in individual subgroups studied.
Correlation of NT-proBNP with hemodynamics and func-
tional capacity
In the total study population, NT-proBNP levels were
significantly correlated with all parameters except CI,
DLCO, PaO2 at peak exercise, and Ve (Table 2). Correla-
tions were strongest for mPAP, PVR, SvO2, 6MWT dis-
tance, number of breaks, work capacity, VO2, O2 pulse,
Ve/VCO2, AaDO2, and Ve/VCO2 slope. When adjusted
for gender, correlations were more or less equal for
hemodynamics and 6MWT parameters in men and
women. However, correlations were stronger in females
for CPET parameters, especially for work capacity and
O2 pulse at peak exercise. When adjusted for age, NT-
proBNP levels were much better correlated with
hemodynamics and functional capacity in older patients
than in subjects ≤65 years. NT-proBNP concentrations
were more strongly correlated with exercise capacity in
PAH compared to CTEPH. No relevant differences were
found when NT-proBNP ratios were used instead of
NT-proBNP levels (data not shown); thus, only correla-
tions with NT-proBNP values are displayed, as they are
much more established in the routine risk stratification
of PH patients.
Table 1 Patients characteristics (n = 84)
Clinical profile
Female / male [n (%)] 46 (54.8) / 38 (45.2)
Age (years) 70.6 ± 1.41
BMI (kg/m2) 27.1 ± 0.60
PHgroup 1 / 3 / 4 / 5 [n (%)] 63 (75) / 7 (8.3) / 12
(14.3) / 2 (2.4)
NT-proBNP
NT-proBNP level (pg/ml) 1500 (38–13,538)
NT-proBNP ratio 7.53 (0.09–60.60)
6-min walking test
Distance (m) 305 ± 14.3
% of norm 62.3 ± 2.72
Breaks (n) 0 (0–6)
Borg scale points (1–10) 4.10 ± 0.29
Right heart catheterization
Mean PAP (mmHg) 41.0 ± 1.22
Cardiac output (l/min) 4.39 ± 0.14
Cardiac index (l/min/m2) 2.43 ± 0.10
PVR (Wood units) 7.40 (3.00–18.2)
Mean RAP (mmHg) 6.0 (1–20)
SvO2 (%) 61.4 ± 0.93
Lung function
DLCO (%) 52.9 ± 2.59
PaO2 at rest (mmHg) 56.8 ± 1.57
PaO2 at peak exercise (mmHg) 57.4 ± 1.84
Cardiopulmonary exercise testing
Work capacity (watts) 47.0 (25–150)
VO2 (ml/min) 953 ± 37.5
VO2/kg 13.0 ± 0.45
AT (ml/min/kg) 9.64 ± 0.40
O2 pulse at peak exercise
(ml/min/beat)
8.30 (3.50–16.0)
Ve (L/min) 52.1 ± 2.11
Ve/VO2 40.5 ± 1.37
Ve/VCO2 47.2 ± 1.58
AaDO2 (mmHg) 49.0 ± 1.76
Vd/Vt (%) 37.1 ± 1.50
Ve/VCO2 slope 44.2 ± 2.06
If not stated otherwise, data is presented as mean ± SEM or as median (range)
BMI: body mass index, NT-proBNP ratio: NT-proBNP level divided by the
age-adjusted normal upper range, PAP: pulmonary arterial pressure, PVR:
pulmonary vascular resistance, RAP: right atrial pressure, SvO2: mixed venous
oxygen saturation, DLCO: lung diffusing capacity for carbon monoxide, PaO2:
arterial oxygen pressure, VO2: peak oxygen uptake, AT: anaerobic threshold, Ve:
peak minute ventilation, Ve/VO2: oxygen equivalent at anaerobic threshold, Ve/
VCO2: carbon dioxide equivalent at anaerobic threshold, AaDO2: alveolar-
arterial oxygen difference at peak exercise, Vd/Vt: functional dead space
ventilation at peak exercise, Ve/VCO2 slope: slope of minute ventilation to
carbon dioxide output
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Discussion
Our study was conducted in order to investigate the
association of serum NT-proBNP with hemodynamics
and exercise capacity in therapy-naive patients with
precapillary PH. NT-proBNP levels were significantly
correlated with most analysed parameters. So far, our
trial confirms the results of previous studies [7].
However, remarkable differences were found when
correlations were adjusted for gender, age and PH
class.
Gender differences in NT-proBNP levels have been de-
scribed before in healthy subjects [8, 9] and in patients
suffering from left heart disease [10]. In these studies,
women show higher plasma concentrations of NT-
proBNP [8, 10] and exhibit a greater increase with age
compared to men [9]. To the best of our knowledge, no
Table 2 Correlation of NT-proBNP with hemodynamics and functional capacity according to gender, age and PH class
Gender Age PH group
Total male female ≤ 65 > 65 PAH CTEPH
n = 84 n = 38 n = 46 n = 24 n = 60 n = 63 n = 12
r r r r r r r
6MWT
Distance (m) −0.430*** −0.435** −0.395** −0.246 −0.403** −0.507*** −0.175
% of norm −0.448*** −0.476** −0.467** −0.295 −0.486*** −0.556*** 0.091
Breaks (n) −0.497*** 0.513** 0.468** 0.173 0.507*** 0.556*** 0.063
Borg scale 0.299** 0.283 0.340* 0.042 0.328** 0.271* 0.573
RHC
mPAP (mmHg) 0.386*** 0.454** 0.318* 0.046 0.581*** 0.341** 0.900***
CO (l/min) −0.342** −0.338* −0.335* −0.495* −0.282* −0,322* −0.625*
CI (l/min/m2) −0.252 −0.183 −0.251 −0.261 −0.255 −0,384* −0.100
PVR (Wood units) 0.460*** 0.543** 0.458** 0.327 0.598*** 0.488*** 0.918***
mRAP (mmHg) 0.243* 0.255 0.231 0.045 0.270 0.215 0.260
SvO2 (%) −0.527*** −0.572*** −0.491** 0.127 −0.544*** −0.530*** −0.528
Lung function
DLCO (%) −0.251 −0.190 −0.385* −0.044 −0.227 −0.332* −0.200
PaO2 rest (mmHg) −0.250* −0.240 −0.307* −0.087 −0.237 −0.312* 0.284
PaO2 exercise
(mmHg)
−0.166 −0.056 −0.233 −0.109 −0.142 −0.221 0.186
CPET
Work (watts) −0.424*** −0.280 −0.533*** −0.364 −0.401** −0.438*** −0.173
VO2 (ml/min) −0.430*** −0.479** −0.375* −0.417 −0.420** −0.492*** −0.035
VO2/kg −0.434*** −0.471** −0.375* −0.220 −0.462*** −0.514*** −0.100
AT (ml/min/kg) −0.294* −0.379* −0.172 −0.319 −0.302* −0.307 −0.618*
O2 pulse
(ml/min/beat)
−0.409*** −0.329* −0.497*** −0.329 −0.459*** −0.373** −0.615*
Ve (L/min) 0.007 −0.021 0.001 −0.081 0.079 −0.024 0.119
Ve/VO2 0.384** 0.336 0.392* 0.791*** 0.280* 0.479*** −0.091
Ve/VCO2 0.451*** 0.351* 0.484** 0.591* 0.386** 0.465** 0.519
AaDO2 (mmHg) 0.398*** 0.354* 0.437** 0.373 0.394** 0.452*** 0.221
Vd/Vt (%) 0.351** 0.266 0.463** 0.274 0.352** 0.349** 0.460
Ve/VCO2 slope 0.427*** 0.445** 0.433** 0.470* 0.441*** 0.471*** 0.671*
Level of significance: * p < 0.05; ** p < 0.01; *** p < 0.001
PH: pulmonary hypertension, IPAH: idiopathic pulmonary arterial hypertension, CTEPH: chronic thromboembolic pulmonary hypertension, 6MWT: 6 min walking
test, RHC: right heart catheterisation, PAP: pulmonary arterial pressure,
PVR: pulmonary vascular resistance, RAP: right atrial pressure, SvO2: mixed venous oxygen saturation, DLCO: lung diffusing capacity for carbon monoxide,
PaO2: arterial oxygen pressure, VO2: peak oxygen uptake, AT: anaerobic threshold, Ve: peak minute ventilation, Ve/VO2: oxygen equivalent at anaerobic threshold,
Ve/VCO2: carbon dioxide equivalent at anaerobic threshold, AaDO2: alveolar-arterial oxygen difference at peak exercise, Vd/Vt: functional dead space ventilation at
peak exercise, Ve/VCO2 slope: slope of minute ventilation to carbon dioxide output
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such differences have been reported in precapillary PH
so far. In our trial, NT-proBNP levels were better corre-
lated with CPET parameters in females compared to
males. In general, exercise capacity is gender dependent
[11], probably reflecting differences in muscle mass [12]
or myocardial geometries and functions [13]. Recently, a
study by Swift and colleagues [14] demonstrated that
male PAH patients have proportionally worse right heart
function despite a similar afterload compared to females.
Thus, gender differences in the adaptive right ventricular
remodelling in response to an impaired lung perfusion
in precapillary PH might partly explain the different as-
sociation of NT-proBNP and functional capacity in
women and men in our trial.
Serum NT-proBNP concentrations increase with age
in a general population, probably reflecting age-related
changes in ventricular compliance, myocardial mass, or
peptide clearance [8]. In contrast, functional capacity de-
clines with age [11, 15]. Nevertheless, in our study,
serum NT-proBNP levels were much better correlated
with hemodynamics and functional capacity in older pa-
tients than in subjects ≤65 years, possibly reflecting a
better cardio-pulmonary reserve in younger PH patients.
Figure 1, for example, illustrates the relation between
serum NT-proBNP levels and the PVR in different age
groups. Whereas older study participants show a linear
correlation between the biomarker and the PVR, serum
levels of NT-proBNP were much lower in younger
patients, even when very high PVR values could be
measured. In general, right heart function declines with
age [16]. In addition, a progressive increase in systolic
PAP can be observed with advancing age even in healthy
subjects [17], probably as a result of an age-associated
blood vessel stiffening in the lungs. Consequently,
increased afterload due to an impaired lung perfusion in
precapillary PH might cause less right ventricular strain
in younger individuals, possibly explaining the inferior
association of serum NT-proBNP levels with disease
severity in younger PH patients.
In our trial, NT-proBNP concentrations were much
stronger correlated with exercise capacity in PAH com-
pared to CTEPH. NT-proBNP indicates right ventricular
pressure overload due to impaired lung perfusion in pre-
capillary PH. For ventilation-derived CPET parameters, an
impaired ventilation/perfusion matching in CTEPH com-
pared to PAH might explain the weaker correlation with
NT-proBNP in CTEPH. Ventilation/perfusion mismatch-
ing results from a more uneven lung perfusion in CTEPH,
possibly due to additional thrombus formation and a more
proximal vascular occlusion [18]. In contrast, PAH repre-
sents a vasculopathy that bilaterally involves distal,
medium to small size arteries [19], resulting in a more
balanced ventilation/perfusion match. As a consequence,
ventilation-derived CPET parameters and serum NT-
proBNP values might be more closely associated in PAH
compared to CTEPH. However, these observations have
to be interpreted with precaution. In our rather small
CTEPH cohort consisting of only 12 patients, con-
comitant diseases, which might limit exercise capacity in-
dependently from PH, might be more prevalent than in
the PAH cohort. Therefore, comorbidity might have
biased our results and might yield a poorer association of
NT-proBNP values with functional capacity in CTEPH
patients.
We admit that our study has limitations. First, the
average age of our study cohort was quite old, possibly
resulting from a small proportion of “typical” idiopathic
PAH patients enrolled in our trial. Advanced age could
Fig. 1 Correlation of NT-proBNP with pulmonary vascular resistance (PVR) in different age groups. Whereas older study participants show a linear
correlation between the biomarker and the PVR, serum levels of NT-proBNP were much lower in younger patients, even when very high PVR
values could be measured (dots in the circle)
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be a relevant confounder in our study. Second, only a
very limited number of PH diagnostic group III and V
patients could be enrolled. Thus, only PAH and CTEPH
patients could be analyzed adequately. However, as only
12 CTEPH cases could be included in the analysis, re-
sults for this cohort are more speculative than for PAH
patients.
Conclusions
Despite these limitations we conclude that in therapy-
naive patients with precapillary PH, serum NT-proBNP
concentrations significantly correlate with disease
severity. However, the association of the biomarker with
hemodynamics and functional capacity might be age-
and gender-dependent. In addition, NT-proBNP may
insufficiently correlate with disease severity, especially in
CTEPH, possibly due to the influence of comorbidity.
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